Burford Brothers Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 6.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 16,569 shares of the company’s stock after acquiring an additional 977 shares during the quarter. Johnson & Johnson comprises 1.4% of Burford Brothers Inc.’s investment portfolio, making the stock its 14th biggest position. Burford Brothers Inc.’s holdings in Johnson & Johnson were worth $2,685,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Innealta Capital LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at about $27,000. Mowery & Schoenfeld Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after acquiring an additional 91 shares during the period. MFA Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $43,000. Fairfield Financial Advisors LTD bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $46,000. Finally, Fairway Wealth LLC lifted its holdings in shares of Johnson & Johnson by 217.1% during the 2nd quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock worth $49,000 after acquiring an additional 228 shares during the period. Institutional investors own 69.55% of the company’s stock.
Insider Buying and Selling
In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on Johnson & Johnson
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $160.88 on Friday. The stock has a fifty day simple moving average of $163.41 and a two-hundred day simple moving average of $155.07. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The firm has a market cap of $387.28 billion, a price-to-earnings ratio of 23.28, a price-to-earnings-growth ratio of 2.90 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter last year, the business posted $2.66 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.08%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- How to Use the MarketBeat Stock Screener
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- High Flyers: 3 Natural Gas Stocks for March 2022
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What Does a Stock Split Mean?
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.